The IASLC Targeted Therapies of Lung Cancer Meeting features novel research on emerging combination immunotherapy approaches and targets. To continue making progress in lung cancer treatment, investigators must keep pushing the science in new directions even as immunotherapy becomes more available in earlier lines. Antibody-drug conjugates appear to have the most activity in those with nonsmall cell lung cancer and HER2 expression. Amedco LLC designates this activity for a maximum of 4.50 ANCC contact hours. We have secured a roster of the top lung cancer researchers in the country, all of whom are approachable, energetic, and engaging experts. IVBH's novel RNA approach to early detection . 2023 Targeted Therapies of Lung Cancer Meeting. All of the relevant financial relationships listed below have been Latest Conference Coverage. Other sponsors included TrendBio, BMG Labtech, Genesearch eFreezer, NanoString, GeneWorks/Akoya, PARITY, FEBS Journal, and the Monash Partners Comprehensive Cancer Consortium. Neoadjuvant, Adjuvant Immunotherapies Poised to Revolutionize Outcomes in Resectable NSCLC. Biomarker test results are crucial for lung cancer patients to understand, but they are difficult to read due to their complexity. We are excited to invite you to join us at the 1st Annual Texas Lung Cancer Conference in Austin, TX at the historic Austin City Limits. Speakers Bureau-Regeneron|Speakers Bureau-Astra Zeneca Astra Zeneca|Consulting Fee-Amgen (Relationship has ended)|Advisor-Janssen (Relationship has ended)|Advisor-BMS (Relationship has ended)|Grant or research support-Astra Zeneca Astra Zeneca|Grant or research support-BMS (Relationship has ended)|Grant or research support-Exelixis|Grant or research support-Genentech, Inc. Eric D. Anderson, MDDirector, Interventional Pulmonology, Professor, Clinical Medicine Division of Pulmonary, Critical Care & Sleep Medicine, Amin Benyounes, MDThoracic Medical Oncologis, Hossein Borghaei, DO, MSChief, Division of Thoracic Medical Oncology, Professor, Department of Hematology/Oncology, Grant or research support-BMS|Grant or research support-Lilly Oncology|Grant or research support-Amgen|Consulting Fee-BMS|Consulting Fee-Lilly Oncology|Consulting Fee-Genentech, Inc.|Consulting Fee-Pfizer, Inc.|Consulting Fee-Merck|Consulting Fee-EMD Serono|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Novartis Pharmaceuticals|Consulting Fee-Genmab|Consulting Fee-Regeneron|Consulting Fee-Amgen|Consulting Fee-Takeda|Consulting Fee-Daiichi Sankyo, Inc.|Consulting Fee-Janssen|Consulting Fee-Natera (Relationship has ended)|Consulting Fee-Pharmamar|Consulting Fee-Beigene|Consulting Fee-Guardant|Consulting Fee-Oncocyte (Relationship has ended)|Consulting Fee-Jazz|Consulting Fee-Da Volterra (Relationship has ended)|Consulting Fee-iTEO (Relationship has ended)|Consulting Fee-Mirati|Consulting Fee-Puma|Consulting Fee-BerGenBio|Other: DSMB-Incyte|Other: DSMB-Springwork|Other: DSMB-Takeda (Relationship has ended)|Other: DSMB-Novartis Pharmaceuticals|Other: DSMB-U of Penn|Stocks or stock options, excluding diversified mutual funds-Sonnetbio|Stocks or stock options, excluding diversified mutual funds-Inspirna|Stocks or stock options, excluding diversified mutual funds-Nucleai|Honoraria-Regeneron (Relationship has ended)|Honoraria-Pfizer, Inc. (Relationship has ended)|Honoraria-Amgen (Relationship has ended)|Honoraria-Daiichi Sankyo, Inc. (Relationship has ended), Ibiayi Dagogo-Jack, MDThoracic Oncologist, Assistant Professor, Medicine, Consulting Fee-Foundation Medicine (Relationship has ended)|Consulting Fee-Bayer Corporation (Relationship has ended)|Consulting Fee-Janssen (Relationship has ended)|Consulting Fee-BMS (Relationship has ended)|Consulting Fee-Genentech, Inc. (Relationship has ended)|Grant or research support-Novartis Pharmaceuticals|Consulting Fee-Pfizer, Inc. (Relationship has ended)|Grant or research support-Pfizer, Inc.|Consulting Fee-Sanofi (Relationship has ended)|Grant or research support-Array BioPharma (Relationship has ended)|Consulting Fee-Xcovery (Relationship has ended)|Consulting Fee-BostonGene (Relationship has ended)|Consulting Fee-Syros (Relationship has ended)|Consulting Fee-Novocure (Relationship has ended)|Consulting Fee-Merus (Relationship has ended), Speakers Bureau-Advanced Accelerator Applications (Relationship has ended), Jill Feldman, MALung Cancer Patient and Advocate, Co-Founder, Consulting Fee-Janssen|Consulting Fee-Blueprint Medicines, Narjust Florez, MDThoracic Medical oncologist, Associate Director, Cancer Care Equity Program, Member of the Faculty, Medicine, Advisor-Regeneron|Advisor-Astra Zeneca Astra Zeneca|Advisor-Daiichi Sankyo, Inc.|Advisor-Novartis Pharmaceuticals|Advisor-Merck|Advisor-Pfizer, Inc.|Advisor-Janssen|Speakers Bureau-Neogenomics, Patrick Forde, M.B.B.Ch.Director, Thoracic Oncology Clinical Research Program, Co-Director, Division of Upper Aerodigestive Malignancies, Associate Professor, Oncology, Marina Chiara Garassino, MBBSDirector, Thoracic Oncology Program, Professor, Medicine, Balazs Halmos, MDDirector, Thoracic/Head and Neck Oncology, Professor, Medicine, Faysal Haroun, MDFellowship Program Director, Assistant Professor, Medicine, Division of Hematology & Oncology, Raffit Hassan, MDChief, Thoracic and GI Malignancies Branch, CCR, NCI, Grant or research support-Bayer Corporation, Chul Kim, MD, MPHThoracic Medical Oncologist, Assistant Professor, Medicine, Ticiana Leal, MDDirector, Thoracic Medical Oncology, Associate Professor, Medicine Department of Hematology & Oncology, Natasha B. Leighl, MD, MMScLung Site Lead, Medical Oncology, Professor, Medicine, Adjunct Professor, Medicine, Benjamin P. Levy, MDThoracic Medical Oncologist, Clinical Director, Medical Oncology; Associate Professor, Oncology, Jessica J. Lin, MDMedical Oncologist, Attending Physician Center for Thoracic Cancers; Attending Physician, Henri and Belinda Termeer Center for Targeted Therapies; Assistant Professor, Medicine, Paid consultant-Nuvalent|Paid consultant-Turning Point Therapeutics|Paid consultant-Bayer Corporation|Paid consultant-Mirati Therapeutics|Paid consultant-Blueprint Medicines (Relationship has ended)|Paid consultant-Elevation Oncology|Paid consultant-Genentech, Inc.|Paid consultant-Novartis Pharmaceuticals (Relationship has ended)|Paid consultant-Pfizer, Inc.|Grant or research support-Hengrui Therapeutics|Grant or research support-Turning Point Therapeutics|Grant or research support-Neon Therapeutics|Grant or research support-Relay Therapeutics|Grant or research support-Bayer Corporation|Grant or research support-Elevation Oncology|Grant or research support-Roche|Grant or research support-Linnaeus Therapeutics|Grant or research support-Nuvalent|Grant or research support-Novartis Pharmaceuticals|Consulting Fee-Regeneron (Relationship has ended), Jennifer A. What Changes Monday Morning? Co-convened by Dr Antonella Papa and Associate Professors Lan Nguyen and Lee Wong from the Monash Biomedicine Discovery Institute (BDI) Cancer Program, the event showcased the latest advancements poised to revolutionise the field. Explain the toxicity associated with targeted therapy given after immunotherapy in EGFR mutant non-small cell lung cancer. Showcase your research and contribute to discussions that will shape the future of treatments in lung cancer and thoracic malignancies. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.50 MOC points in the American Board of Internal Medicines (ABIM) Maintenance of Certification (MOC) program. We hope you enjoyed the education and the discussions. Find here instructions to assist with your presentation. A comprehensive overview of the most significant advances in the treatment of lung cancer, as well as valuable take-home information, will be discussed. Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual patients. MedStar Health adheres to the ACCMEs Standards for Integrity During this years event, participants could review the current state-of-the-art in lung cancer therapy, update their knowledge in prevention, screening, detection and much more. Register for WCLC 2023 Follow the IASLC on WeChat This two-day CE event will review the latest advances in lung cancer focused on what a medical oncologist needs to know to provide stateofthe art care today. It is our great pleasure and honor to extend a warm invitation to attend and participate in the IASLC 2023 World Conference on Lung Cancer (#WCLC23) to be held in Singapore from September 9 - 12, 2023. Forde Recaps Chemoimmunotherapy Activity in PD-L1Negative NSCLC. Vincent Lam, MD, describes frontline indications for this patient population, as well as strategies that can be utilized to overcome TKI resistance in later lines of therapy. In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers. Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech, Inc. Elaine Shum, MDMedical Oncologist, Assistant Professor, Medicine, Advisor-AstraZeneca AstraZeneca|Advisor-Boehringer Ingelheim|Advisor-Blueprint Medicines|Grant or research support-Delfi Diagnostics, Jonathan Spicer, MDDirector, Thoracic Oncology Biobank, Medical Director, McGill Thoracic Oncology Network, Program Director, Advanced Thoracic and Upper GI Surgical Oncology Fellowship, Assistant Professor, Surgery, Alexander I. Spira, MD, PhD, FACPDirector, Thoracic and Phase I Program, Co-Director, VCS Research Institute, Clinical Assistant Professor, Oncology, Brendon M. Stiles, MDAssociate Director, Surgical Services, Professor and Chief, Thoracic Surgery and Surgical Oncology, Irina G. Veytsman, MDSection Director, Hematology/Oncology Medical Oncologist, Randi M. Williams, PhD, MPHAssistant Professor, Oncology, Ann E. Hwalek, DO, MSAttending Physician, Thoracic Surgery, Assistant Professor, Medicine, Laura Macke, FNP-C,MS,BSNMedical Oncologist, Jillian E. Thompson, ANP-BC, AOCNPNurse Practitioner, Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals (Relationship has ended), Marybeth V. Kazanas, PharmDSenior Director, Clinical Pharmacy Services. This symposium is not certified for continuing education credit. Russell Kenneth Hales, MD, discusses the role of multidisciplinary care in locally advanced lung cancer. Upal Basu Roy, PhD, MPH, discusses addressing barriers to biomarker testing in lung cancer. Born from feedback received during meetings with our Corporate Partners in 2022, the IASLC Corporate Roundtable brings IASLC leadership and Roundtable Member Representatives together to collaborate on solutions to big-picture challenges facing those working to conquer lung cancer and other thoracic malignancies. ASH Webinar, 2023 What Changes Monday Morning? Includes the Gate + Alcheme of Instant Change. Free oncology conference and content updates weekly. The IASLCs latest Atlas provides a comprehensive overview of all current and emerging molecular targets, specimen acquisition, available assays, and reporting and interpretation of molecular testing results from both a diagnostic and clinical perspective. Nurses should claim only the credit commensurate with the extent of their participation in the activity. . Immunotherapy plus chemotherapy is a standard of care for patients with advanced PD-L1negative nonsmall cell lung cancer who do not harbor actionable driver mutations. Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment. Discuss the current application of liquid biopsy (or ctDNA analysis). IASLC 2023 North America Conference on Lung Cancer, JTO Clinical and Research Reports (JTO CRR), IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer, Career Development and Fellowship Committee, Nurses and Allied Health Professionals Committee, Tobacco Control and Smoking Cessation Committee. Recognize unique toxicities associated with targeted agents used in NSCLC. Sessions with important updates on targeted therapy and immunotherapy will feature recognized experts in the field and there will be a debate over use of emerging biomarkers to guide treatment of advanced NSCLC. Present & Discuss Individuals in a position to control the content of this CE ESMO is a Swiss-registered not-for-profit organisation. Register by June 9, 2023 (23:59 PST) for the best pricing! This innovative and state of the art program will feature some of the world's leading lung cancer experts to present the latest research and strategies for the care of lung cancers incorporating data from the major oncologic annual meetings. The latest lung cancer and thoracic malignancies research, new technologies & innovations will be presented across a 4-day in-person or virtual program. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to. Pharmacists:This activity is approved for 7.50 contact hours. Mon, 12 Jun 2023 - Tue, 13 Jun 2023. This activity was planned by and for the healthcare team and learners will receive 7.50 Interprofessional Continuing Education (IPCE) credits for learning and change. Presentations will summarize information about ongoing clinical trials of the newest therapies for lung cancer including data on preclinical and early clinical data. Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development. ineligible company is any entity whose primary business is producing, marketing, Strategizing Effective Ways to Overcome TKI Resistance in ALK+ NSCLC. Immunotherapy Must Become More Precise and Personalized in Lung Cancer. activity, including faculty, planners, reviewers, or others are required to From provision of educational events around the world and virtually to research projects and publications that advance the science of lung cancer, the IASLC's membersconsisting of medical, surgical, and radiation oncologists, as well as other thoracic oncology specialists such as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient research advocates, patients, and their caregiversare raising the bar for care of patients with lung cancer. Join us to discuss and present new and emerging data on immunoresistance in NSCLC! Additionally, the Isabella & Marcus Foundation, a devoted philanthropic organisation spearheading research into paediatric brain cancer, stood as a longstanding partner of CSTI. IASLC | International Association for the Study of Lung Cancer Early Registration for WCLC 2023 Is Now Open! Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. selling, re-selling, or distributing healthcare products used by or on The 2020 US Surgeon Generals Report reported that smoking cessation after a cancer diagnosis is associated with improved survival, and quitting smoking significantly benefits non-cancer-related health outcomes. Exceptional Education Presentations will summarize information about ongoing clinical trials of the newest therapies for lung cancer including data on preclinical and early clinical data. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Explain the approved use of targeted therapy for KRAS-mutant non-small cell lung cancer. Please click the link below and login to watch at your convenience. As more agents are evaluated either in addition to or following PD-1/PD-L1 inhibitors, more information may be learned about how best to leverage alternate biomarkers, according to Marina C. Garassino, MD. The NACLC 2023is a dynamic meeting with a long tradition and will feature the most up-to-date research, diverse topics of interest, and educational sessions with leading experts. }); After completing this activity, the participant will be able to: Name of Ineligible Company(s) / Nature of Relationship(s), Stephen V. Liu, MDDirector, Thoracic Medical Oncology, Director, Phase I Developmental Therapeutics, Associate Professor, Medicine, Activity Co-Director Content Reviewer, Faculty, Advisor-Amgen|Advisor-AstraZeneca AstraZeneca|Advisor-AbbVie|Advisor-BMS|Advisor-Catalyst (Relationship has ended)|Advisor-Daiichi Sankyo, Inc.|Advisor-Eisai|Advisor-Elevation Oncology|Advisor-Genentech, Inc.|Advisor-Gilead Sciences, Inc.|Advisor-Guardant Health|Advisor-Janssen|Advisor-Jazz Pharmaceuticals|Advisor-Merus|Consulting Fee-Merck|Advisor-Novartis Pharmaceuticals|Advisor-Regeneron|Advisor-Sanofi|Advisor-Takeda|Advisor-Turning Point Therapeutics|Grant or research support-Alkermes|Grant or research support-Elevation Oncology|Grant or research support-Genentech, Inc.|Grant or research support-Gilead Sciences, Inc.|Grant or research support-Merck|Grant or research support-Merus|Grant or research support-Nuvalent|Grant or research support-RAPT|Grant or research support-Turning Point Therapeutics, Nagla F. Abdel Karim, MDMedical Oncologist. Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2, Early Breast Cancer, Retrospective Study Confirms Real-World Efficacy of Brexucabtagene Autoleucel in R/R B-ALL, Dr Garcia-Manero on Luspatercept in Lower-Risk MDS, Dr Zeidan on Imetelstat in Lower-risk MDS, OncLive National Fellows Forum: Lung Cancer 2023, Join us in Chicago for Giants of Cancer Care, | Join us in Chicago for Giants of Cancer Care. Surgical resection remains the key treatment modality for early-stage nonsmall cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients. Professor Daly said, The line-up of local, national and international speakers was amazing! Dr. Hales on Investigational Treatment Strategies to Build Upon the PACIFIC Trial Results in Stage III NSCLC. Welcome | Australian Lung Cancer Conference 2023 Welcome Towards 2030 - a decade of transformation in lung cancer On behalf of the Lung Foundation Australia, we warmly invite to you to be part of the 9th Australian Lung Cancer Conference to be held on the beautiful Gold Coast, Queensland from 15-17 February 2023. #ASCO23 June 2-6, 2023 McCormick Place Chicago, IL & Online Abstracts Now Available With research spanning all major disease sites and research areas, you can stay up-to-date on clinical trials, cutting-edge research, and global perspectives on the most sought-after innovation in oncology. Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung Cancer. An The IASLC PR Project was created to establish Pathologic Response (PR), Major Pathologic Response (MPR), and/or Complete Pathologic Response (CPR) in surgical resection specimens following neoadjuvant therapies as predictors of long-term clinical benefit in patients with resected stages I to III lung cancers. The substantial body of research reviewed in the 2014 US Surgeon Generals Report concluded that smoking by cancer patients and survivors causes adverse outcomes, including increased overall mortality and cancer-related mortality, greater risk of a second primary cancer, and associations with substantially worse toxicity from cancer treatments. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. The 2023 Great Debates and Updates in Lung Cancers is a multi-day, debate-driven conference focusing on the treatment of thoracic oncology. March 30 - April 1, 2023 ACL Live at the Moody Theater in Austin, Texas @TLCconference #TexasLung23 Endorsed by Accredited by Presented by TLC Conference Chairs We are excited to invite you to join us at the 1st Annual Texas Lung Cancer Conference in Austin, TX at the historic Austin City Limits. Synergizing EGFR TKIs with antiangiogenic agents and chemotherapy, as well as improving the use of molecular classification, are novel strategies aimed at taking the frontline setting for patients with EGFR-mutant nonsmall cell lung cancer to the next level. Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with lung cancer. #ASCO23 Repeat histologic evaluation and molecular testing in patients with EGFR-mutant nonsmall cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions. Dr. Brahmer on Determining When to Start Immunotherapy in Frontline NSCLC. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer. "The CSTI Conference has been a great success, and we are thrilled to have been part of this incredible event.". Dr. Hales on the Role of Multidisciplinary Care in Locally Advanced Lung Cancer. and Independence in Accredited Continuing Education. Emerging TKIs Shake Up the Treatment Landscape for EGFR Exon 20 Insertion+ NSCLC. Describe current standard care for advanced mesothelioma. Why Attend TTLC 2023? including lung cancer evolution and environmental factors (Professor Charles Swanton, Francis Crick Institute), new . WCLC 2023 Early Registration Closes June 9, 2023. Summarize strategies for navigating conversations with patients and families. Testament to the strength of the institutes cancer research, three BDI investigators, Associate Professor Meredith OKeeffe, Dr Dustin Flanagan and Dr Sungyoung Shin were among the invited speakers, and many presentations featured collaborations with BDI scientists., About the Monash Biomedicine Discovery Institute Committed to making the discoveries that will relieve the future burden of disease, theMonash Biomedicine Discovery Institute (BDI)at Monash University brings together more than 120 internationally-renowned research teams. The Texas Lung Cancer Conference promises to be one of the biggest lung cancer events of the year. The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. IASLC LinkedInFacebookTwitter Instagram IASLC , 2023 HOT TOPIC IN BASIC & TRANSLATIONAL SCIENCE: RESISTANCE TO IO IN NSCLC. Identify nursing strategies for early detection of immune-mediated toxicities. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. This accolade recognises excellence in translational research and was awarded to Professor Sherene Loi of the Peter MacCallum Cancer Centre. Russell Kenneth Hales, MD, discusses investigational treatment strategies that have the potential to build upon the positive results of the phase 3 PACIFIC trial in stage III nonsmall cell lung cancer. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CARIBOU, Maine On Thursday, May 18 Cary Medical Center hosted the virtual conference "Turning the Tide on Lung Cancer" highlighting the importance of low dose CT lung cancer screening. We hope to see you there! Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer. News provided by. This site uses cookies. This conference is brought to you byIDEOlogy Health. In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Researchers examine emerging data demonstrating that functionally distinct arrhythmia classes are associated with radiotherapy dose to discrete cardiac substructures. Lara is now a student in the UC Davis School of Medicine, which, for him . It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Rising Standards in Regulatory Decisions Highlight Challenges in Drug Development in Lung Cancer. The ESMO Daily Reporter is the official ESMO newspaper providing live reporting, highlights, critical insights on data presented at ESMO congresses, and expert opinions on controversial topics. Lung Cancer Conference will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. Abundance of Immunotherapy Combinations Leaves Treatment Selection Unclear in Advanced NSCLC. Sessions will cover the basics (What is NGS?) and the advanced (How can we predict and prevent acquired resistance?), making this conference appropriate for all levels of training and experience. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. September 1-4, 2023. These observations may help guide potential mitigation efforts for lung cancer patients undergoing radiotherapy. Awardee Sherene Loi (fourth from left) with Prof Roger Daly (far left), Beate Lackmann (right of Sherene) and the Co-convenors. Durvalumab Delivers Durable Benefit, Regardless of PD-L1 Expression, in NSCLC. Home - 2023 Targeted Therapies of Lung Cancer Meeting Save the date for ttlc 2024! Register today to gain exclusive insights into the latest therapies for lung cancer through ongoing clinical trials, presented by global thought leaders. American Board of Internal Medicine MOC Credit. These recommendations are intended as guidance for clinical trials, although it is hoped they can be viewed as suggestions for good clinical practice outside of clinical trials, to improve the consistency of pathologic assessment of treatment response. Contributed May 30, 2023. Physicians:MedStar Health designates this live activity for a maximum of 7.50AMA PRA Category 1 Credits. Immunotherapy Advances Drive Progress in Lung Cancer Treatment. Showcase your research and contribute to discussions that will shape the future of treatments in lung cancer and thoracic malignancies. The IASLC invites you to be a part of IASLC's ongoing success story and join us in Singapore for an exciting program with wide-ranging and multidisciplinary content. 8,000+ members from over 100 countries, all united by a single goal: to conquer thoracic cancers worldwide. The IASLC Staging Project is a global effort to study and improve the current staging system for lung cancer, mesothelioma, thymic and esophageal cancer. 2022 was a mix of old and new. Enter your Email address and click submit to have a login reset link sent to you. San Antonio Breast Webinar, Total Health Conferencing brings you the very best in, 2023 Cancer Updates Lung Cancer Dinner Program, 2023 Oncology Nursing Society Metro Denver Chapter Conference, 2023 Spring Oncology Education Retreat Lake Tahoe, 2023 Community Oncology Educational Discussion Series Fort Lauderdale, Diversity, Equity, and Inclusion: Primary Care to OncologyConversations for Change, 2023 University of Kansas Cancer Center Breast Cancer Year in Review.
Baby Girl Ruffle Onesie,
Yamaha Pacifica Package,
Articles L